Article · 13 Nov 2026
ArticlePublished 2008
Erlotinib-Induced Skin Rash. Pathogenesis, Clinical Significance and Management in Pancreatic Cancer Patients
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Erlotinib is a tyrosine kinase inhibitor with anti epidermal growth factor receptor activity, approved as first line treatment concurrently administrated with gemcitabine for locally advanced unresectable or metastatic pancreatic cancer. One of the most common side effects, rash, is possibly linked to overall and progression-free survival and may sere as a potential surrogate marker. Nevertheless, erlotinib-induced rash is cause of negative impact on patients' quality of life and often can trigger discontinuation of treatment. Adequate and timely management of rash depending on the grade of rash is important for therapy continuation.
Subjects
Gastroenterology & HepatologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of the Pancreas.
Article · 25 Jun 2026
Comparative outcomes of Open and Laparoscopic drainage in Walled off Pancreatic Necrosis
Article · 24 Feb 2026
Xanthogranulomatous Pancreatitis Showing Overlapping
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of the Pancreas
- SubjectGastroenterology & Hepatology
- BylineArticles whose byline prints “Kostas Syrigos”
- BylineArticles whose byline prints “Muhammad Wasif Saif”
- BylineArticles whose byline prints “Irene Merikas”
- BylineArticles whose byline prints “Sotirios Tsimboukis”